Advances in Liquid Biopsy for Diagnosis, Surveillance, and Treatment Response | MGR | 1 April 2026

Why It Matters

Liquid‑biopsy advances promise earlier, less invasive cancer detection and precise treatment monitoring, potentially reducing unnecessary procedures and accelerating therapeutic decisions.

Key Takeaways

• Liquid biopsies analyze cell‑free DNA/RRNA to monitor tumor genetics non‑invasively.
• Multi‑cancer early detection shows high false‑positive rates, especially for lymphoid cancers.
• Epigenetic epicseek infers gene expression from chromatin, achieving >90% classification.
• Tumor‑informed ctDNA panels correlate with burden and predict outcomes beyond diagnosis‑to‑treatment interval.
• RNA profiling expands liquid biopsy to monitor injury, like COVID lung damage.

Summary

The talk reviewed recent advances in liquid‑biopsy technologies, focusing on how cell‑free DNA and RNA in plasma can serve as a non‑invasive window into tumor genomics, epigenomics, and transcriptomics. Ashis highlighted three clinical arenas—early cancer detection, treatment monitoring, and organ‑injury assessment—illustrating the breadth of applications now emerging from Stanford’s research pipeline. Key data points included the Pathfinder study’s 1.4% positive rate among 6,000 average‑risk adults, with more than half of positives turning out false, and a striking 24% prevalence of undiagnosed lymphoid malignancies in a 100,000‑person cohort. The speaker contrasted broad, unbiased approaches (whole‑genome bisulfite sequencing, cell‑free RNA profiling) with targeted methods such as the epicseek epigenetic assay, which infers transcriptional activity from chromatin accessibility and achieved >90% accuracy in classifying ten lymphoid subtypes. Tumor‑informed ctDNA panels (capseek) demonstrated strong correlation with traditional PET‑derived tumor burden metrics and outperformed diagnosis‑to‑treatment interval as a prognostic indicator. Notable examples featured a 750‑patient validation of epicseek that correctly assigned tissue of origin in 90% of cases, and RNA‑based lung‑injury signatures that distinguished COVID‑19 ARDS, COPD, and ventilator‑associated damage. Ashis quoted, “A single blood tube can replace a tissue biopsy when the latter is unsafe or impractical,” underscoring the clinical promise of these assays. The implications are clear: liquid biopsies are moving from exploratory research toward actionable diagnostics, enabling earlier detection, real‑time therapeutic monitoring, and even non‑cancer organ health surveillance. As specificity improves and false‑positive rates decline, payers and regulators will likely integrate these tests into standard oncology pathways, reshaping patient management and drug development timelines.

Original Description

This Stanford Department of Medicine Grand Rounds (MGR) presentation is entitled "Advances in Liquid Biopsy for Diagnosis, Surveillance, and Treatment Response," and took place April 1, 2026 on Stanford campus.

Presenter Ash Alizadeh, MD, PhD, is a leading physician-scientist at Stanford specializing in cancer immunology, utilizing advanced genomic technologies, including liquid biopsies, and AI-driven approaches to develop novel therapeutics and enhance patient outcomes.

Learn more about the MGR series at: https://medicine.stanford.edu/education/medicine-grand-rounds.html